Acasti Pharma Inc
For the period ended Mar 31, 2024. Filed Jun 21, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Jun 21, 2024
GRCE$1.86-0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
| Year ended March 31, 2024 | Year ended March 31, 2023 | |
|---|---|---|
| (Expressed in thousands, except share and per data) | $ | $ |
| Operating expenses | ||
| Research and development expenses, net of government assistance | (4,683) | (9,972) |
| General and administrative expenses | (6,432) | (7,614) |
| Sales and marketing | (252) | (661) |
| Restructuring cost | (1,485) | — |
| Impairment of intangible assets | — | (28,682) |
| Impairment of goodwill | — | (4,826) |
| Impairment of assets held for sale | — | (400) |
| Loss from operating activities | (12,852) | (52,155) |
| Foreign exchange loss | (16) | (72) |
| Change in fair value of derivative warrant liabilities | (2,728) | 10 |
| Interest income and other expense, net | 911 | 246 |
| Total other income (expense), net | (1,833) | 184 |
| Loss before income tax benefit | (14,685) | (51,971) |
| Income tax benefit | 1,832 | 9,542 |
| Net loss and total comprehensive loss | (12,853) | (42,429) |
| Basic and diluted loss per share | (1.35) | (5.71) |
| Weighted average number of shares outstanding | 9,529,123 | 7,435,472 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.